Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
about
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPaseComparison of indicators of iron deficiency in Kenyan children.TfR1 interacts with the IKK complex and is involved in IKK-NF-κB signallingPACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR ExpressionRegulation of iron homeostasis by microRNAs.MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats.Diagnostic and prognostic markers in differentiated thyroid cancer.Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions.Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients.Caffeine Prevents Blood Retinal Barrier Damage in a Model, In Vitro, of Diabetic Macular Edema.Differential expression of PARK2 splice isoforms in an in vitro model of dopaminergic-like neurons exposed to toxic insults mimicking Parkinson's disease.
P2860
Q33914771-FA9F576C-276F-4D14-9CB4-3FAAD2E969D5Q35690041-DB031DDB-518F-4DD1-9378-397CBE55D324Q35786026-FB758EDB-AF19-4D99-9999-B2028FF62978Q36179308-F592D2EC-A0B1-49BD-ADCC-58A1F39FAFB4Q36420899-87CC42EB-FBEF-4990-90AD-0C8FDBFADCFAQ36509188-8300D1E2-2FD8-419B-92E1-4E28435EF282Q36948641-4D5E6D38-DE98-4861-96F0-BF4BCF76AEEFQ38017136-067EA6DF-6AA9-40A5-9145-770F92B8F083Q38132116-F201B7D9-5C1E-481F-B5CC-4D513176E8F9Q39137563-C569B988-C864-4721-98DC-0A7EBD6173DCQ40819992-4613A0A3-6F60-49A5-AFF8-8AFB855B7C74Q42010649-1B9E69D7-5963-4459-A558-A8D0BBB04ED7Q47109274-CC2FA436-893A-4ACB-94BF-32CD8A76FF82Q47993545-7FE82E7B-D174-4103-BBD9-A7010830CA35Q48157376-5E47A1BD-4ACB-4415-9638-0476680F1E6D
P2860
Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@en
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@nl
type
label
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@en
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@nl
prefLabel
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@en
Aberrant expression of TfR1/CD ...... marker and therapeutic target.
@nl
P2093
P50
P356
P1433
P1476
Aberrant expression of TfR1/CD ...... marker and therapeutic target
@en
P2093
Antonietta Torrisi
Daniele Recupero
Giada Maria Vecchio
Maria Teresa Mucignat
Paolo Amico
Roberto Perris
P304
P356
10.1089/THY.2010.0173
P577
2011-02-16T00:00:00Z